Rheumatology

Calculators and clinical decision support

RA treatment, corticosteroid conversion, NSAID selection, pain, renal function, and bone-health support

The existing portal lists four calculators without distinguishing disease-management algorithms from arithmetic or supportive tools. We preserve access while explicitly identifying evidence status.

Rheumatoid arthritis

Early diagnosis, treat-to-target care, csDMARDs, biologic therapy, targeted synthetic DMARDs, and safety monitoring

RA management requires confirmation of inflammatory synovitis, assessment of serology and prognostic factors, measurement of disease activity, early disease-modifying treatment, and iterative adjustment toward an appropriate clinical target. Persistent symptoms should be evaluated for active inflammation, structural damage, fibromyalgia, osteoarthritis, infection, medication adverse effects, and other mimics.

Psoriatic arthritis and axial spondyloarthritis

Peripheral arthritis, enthesitis, dactylitis, axial disease, skin/nail disease, and domain-based therapy

Psoriatic arthritis and axial spondyloarthritis require attention to musculoskeletal phenotype, psoriasis, nail disease, inflammatory bowel disease, uveitis, cardiometabolic comorbidity, prior biologic exposure, infection risk, and the clinical domain driving treatment. Methotrexate response in peripheral arthritis should not be extrapolated to axial disease.

Systemic lupus erythematosus and lupus nephritis

Organ-specific disease activity, hydroxychloroquine, immunosuppression, biologic therapy, and kidney involvement

SLE treatment should be matched to organ involvement and severity. Constitutional symptoms, pain, fatigue, and patient-reported disease burden require interpretation alongside objective evidence of inflammatory activity because fibromyalgia and other noninflammatory conditions can coexist and can inflate subjective disease-activity measures.

Gout and crystal arthritis

Flare treatment, urate-lowering therapy, treat-to-target care, prophylaxis, kidney disease, and medication contributors

Gout management includes acute flare treatment, appropriate indications for urate-lowering therapy, low-dose initiation with titration, serum-urate monitoring, anti-inflammatory prophylaxis during initiation when indicated, adherence, diet/alcohol counseling, kidney function, and review of medications that may raise urate.

Osteoarthritis

Exercise, weight management, topical and oral analgesia, injections, function, and surgical referral

Osteoarthritis management is multimodal and should be matched to joint site, symptom burden, function, comorbidity, patient preference, and structural disease. Pharmacologic treatment should not displace exercise, physical therapy, weight management when appropriate, assistive strategies, and timely orthopedic evaluation when symptoms remain severe.

Vasculitis, systemic sclerosis, myositis, Sjogren disease, and autoimmune ILD

Organ-threatening systemic disease requires disease-specific assessment and multidisciplinary care

Systemic rheumatic diseases can involve the kidney, lung, nervous system, skin, muscle, heart, blood vessels, eye, and gastrointestinal tract. Treatment intensity depends on the disease subtype, organ involvement, severity, relapse risk, and expected toxicity of immunosuppressive therapy.

Juvenile idiopathic arthritis and pediatric rheumatology

New 2026 ACR JIA guidance, growth, uveitis, medication safety, and transition to adult care

Pediatric rheumatology differs from adult care through growth, development, weight-based dosing, vaccination, school participation, uveitis risk, reproductive counseling during adolescence, family involvement, and transition planning. Disease-modifying treatment should be aligned with the childs specific JIA phenotype and current pediatric guidance.

Fibromyalgia and noninflammatory pain

Distinguish centralized pain, structural disease, and active inflammatory rheumatic disease

Fibromyalgia can coexist with RA, SLE, osteoarthritis, hypermobility, and other rheumatic disease. Tenderness, fatigue, poor sleep, cognitive symptoms, and diffuse pain can substantially increase patient-reported disease burden without necessarily reflecting active synovitis or organ inflammation.

Osteoporosis and glucocorticoid-induced bone loss

Fracture risk, glucocorticoid exposure, calcium/vitamin D, antiresorptive therapy, and anabolic treatment

Rheumatology patients may have elevated fracture risk from age, inflammatory disease, immobility, menopause, low body mass, prior fracture, and glucocorticoid exposure. Bone protection should be considered when systemic glucocorticoids or other risk factors are expected to persist.

Immunomodulatory therapy safety

Vaccination, infection screening, reproductive health, organ-function monitoring, and perioperative planning

Safe immunomodulatory therapy requires more than medication selection. Vaccination status, tuberculosis and hepatitis risk, infection history, reproductive plans, malignancy history, laboratory monitoring, cardiovascular risk, kidney and liver function, and perioperative timing can materially affect the choice and timing of therapy.

Rheumatologic pharmacotherapy

GlobalRPh DMARD, biologic, anti-inflammatory, gout, and bone-health drug references

We retain the medication tables from the existing Rheumatology portal but group them by clinical role and label older resources for modernization. Current disease management should be anchored to current guidance and current product labeling rather than to historical drug tables alone.

GlobalRPh Rheumatology article library

Current and established reviews in inflammatory and musculoskeletal disease

The existing portal surfaces only six older articles. We now include current work on RA phenotype, treatment selection, PsA, lupus/fibromyalgia overlap, nailfold/systemic disease clues, reproductive health, tele-rheumatology, and related inflammatory disorders.

GlobalRPh rheumatology video development

Priority topics for clinician education

The existing Rheumatology portal has an empty video section. We identify priority topics for a dedicated clinician-focused Rheumatology video library rather than populating the section with unrelated material.

Clinical content modernization

Priority updates within the GlobalRPh Rheumatology library

Our Rheumatology section contains longstanding medication tables and calculators, but several were created under older guideline, product, and safety frameworks. We plan to preserve useful clinical reference material while updating evidence, current products, monitoring, terminology, and disease-specific positioning.

Current external clinical standards

Authoritative rheumatology guidance integrated with GlobalRPh resources

Rheumatology treatment evolves rapidly as new biologics, targeted therapies, safety data, and organ-specific strategies emerge. We provide direct access to current professional guidance while progressively modernizing individual GlobalRPh drug and disease resources.

Supporting GlobalRPh clinical resources

Nephrology, pulmonary, dermatology, hematology, endocrinology, pain, pediatrics, and infectious-disease support